Researchers have engineered a genetic system capable of detecting the mechanical softness of tumour cells and reprogramming that physical state into a synthetic antigen target, offering a new conceptual framework for tackling treatment-resistant cancer stem-like cell populations in solid tumours.
Researchers have developed a genetic system that could help CAR T cells overcome a previously underappreciated form of resistance in solid tumours: the physical softness of cancer cells.
The preclinical study, published in Nature Biomedical Engineering, identifies a link between soft tumour environments, cancer stem-like states and reduced susceptibility to CAR T-cell killing. The researchers then engineered the cells to turn that mechanical state into a synthetic target for immune attack.
Why does this matter for early drug discovery?
CAR T-cell therapy has drastically improved treatment for several blood cancers but has proved much harder to translate successfully to solid tumours. One reason is the biological and physical diversity within solid tumour environments.
Previous research has shown that mechanically soft tumour-repopulating cells can resist cytotoxic T-cell killing because their physical properties interfere with the formation of membrane pores created by perforin.
The new work takes that observation a step further. The team developed a genetic ’Mechano-Recorder’ that detects calcium signalling associated with soft environments and converts it into a stable fluorescent signal. This effectively creates a molecular record of which cells have experienced softness.
“The recording part is the most exciting part,” said co-author Longwei Liu. “It’s just like you’re taking a picture of the cancer cells at a certain time points and recording the signal for diagnostic purposes or for developing a therapeutic purpose.”
The researchers found that cells identified by the recorder showed features associated with stemness, epithelial-mesenchymal transition and hypoxia.
What is a Mechano-Recorder?
A Mechano-Recorder is a genetically engineered system designed to record how a cell responds to its physical surroundings. In this study, it detects calcium signalling associated with a soft tumour environment and converts that short-lived signal into a longer-lasting molecular marker. This allows researchers to identify cells that have experienced mechanical softness even after the original stimulus has changed.
From biomarker to ’kill me’ signal
The most significant step was to reprogramme the system rather than simply use it to identify resistant cells.
The researchers replaced the fluorescent reporter with CD19, an antigen already used as a target for CAR T therapies in blood cancers. Softness-responsive cancer cells could therefore be engineered to display CD19 and become recognisable to CD19-directed CAR T cells.
“What we are trying to do is firstly recognise the difference between the softer and the stiffer cells and then we rewire the softer cells to express another synthetic antigen,” said lead author Jenny Yunjia Qu. “When the softer cells express this signal, the CD19 CAR T cells that we engineered will come in and only see those cells with the ‘kill me’ signal, and then they’ll attack,” Qu said.
Key takeaways
- The research is preclinical: The approach has so far been tested in cancer cell lines, patient-derived cells and mouse models, not in human clinical trials.
- Tumour softness may drive resistance: The researchers found that softer cancer cells were more likely to develop stem-like characteristics associated with treatment resistance.
- The Mechano-Recorder acts as a cellular sensor: It detects calcium signalling associated with a soft environment and converts it into a persistent molecular record.
- The system can turn resistance into a target: Researchers replaced the fluorescent reporter with CD19, enabling CAR T cells to recognise and attack the previously evasive cells.
- The concept could extend beyond breast cancer: The researchers report testing the approach in models of glioblastoma, pancreatic cancer and prostate cancer.
- Clinical translation remains a long way off: Questions around delivery, specificity, safety and whether the approach works in humans will need to be addressed before clinical testing.
How does this fit within the field?
The concept builds on growing interest in cancer mechanobiology, which involves understanding how physical properties like stiffness and mechanical forces influence tumour behaviour. Earlier studies, Such as this 2021 study, published in Cancer Research, had already linked cellular softness with stem-like cancer states and immune resistance. This particular study found that soft tumour-repopulating cells were more resistant to cytotoxic T-cell killing, suggesting that the physical properties of cancer cells can affect how effectively immune cells are able to attack them.
The new study connects those observations to a synthetic biology strategy that actively converts a resistance mechanism into an immunotherapy target.
The study also presents a potential framework for identifying difficult-to-target tumour cell populations based on their biological history rather than relying solely on conventional surface markers. The researchers demonstrated the system in breast cancer cell lines, patient-derived cells and mouse models, with improved elimination of soft cancer stem-like cells.
However, due to the preclinical nature of this research, it will require more investigation before the engineered system can be potentially tested in humans. The next major steps will be determining whether the genetic circuitry can be delivered safely and selectively in vivo and whether unwanted CD19 expression can be avoided.
No comments yet